Literature DB >> 33363017

Prognostic Role of the Activated p-AKT Molecule in Various Hematologic Malignancies and Solid Tumors: A Meta-Analysis.

Zhen Yao1, Guangyu Gao1, Jiawen Yang2, Yuming Long1, Zhenzhen Wang1, Wentao Hu3,4, Yulong Liu1,3,4.   

Abstract

Cancer is one of the main causes of human death worldwide. Recently, many studies have firmly established the causal relationship between oxidative stress and cancer initiation and progression. As a key protein in PI3K/Akt signaling pathway, p-AKT (phosphorylated Akt) participates in the process of oxidative stress and plays a prognostic role in various hematologic tumors and solid tumors. We conducted a comprehensive search of the PubMed, Embase and Cochrane libraries to identify studies published in the past decade involving cancer patients expressing p-AKT that reported overall survival (OS) during follow-up. In this study, 6,128 patients in total were evaluated from 29 enrolled articles, and we concluded that overexpression of p-AKT was closely related to worse OS in cancer patients with a hazard ratio (HR) of 2.33 (95% CI: 1.67-4.00). Furthermore, we conducted a subgroup analysis, and the results indicated that overexpression of p-AKT was associated with worse OS in hematological tumor (HR: 1.64, 95% CI: 1.41-1.92), and solid tumor (HR: 2.44, 95% CI: 1.61-5.26). High expression of p-AKT is related to poor prognosis of various hematologic tumors and solid tumors.
Copyright © 2020 Yao, Gao, Yang, Long, Wang, Hu and Liu.

Entities:  

Keywords:  biomarker; meta-analysis; oxidative stress; p-AKT; tumor

Year:  2020        PMID: 33363017      PMCID: PMC7758503          DOI: 10.3389/fonc.2020.588200

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  42 in total

1.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.

Authors:  Andreas Stang
Journal:  Eur J Epidemiol       Date:  2010-07-22       Impact factor: 8.082

2.  The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases.

Authors:  J Y Hong; M E Hong; M K Choi; Y S Kim; W Chang; C H Maeng; S Park; S J Lee; I-G Do; J-S Jo; S H Jung; S J Kim; Y H Ko; W S Kim
Journal:  Ann Oncol       Date:  2014-01       Impact factor: 32.976

3.  Analysis of PIK3CA mutations and PI3K pathway proteins in advanced gastric cancer.

Authors:  Chie Ito; Satoshi S Nishizuka; Kazuyuki Ishida; Noriyuki Uesugi; Tamotsu Sugai; Gen Tamura; Keisuke Koeda; Akira Sasaki
Journal:  J Surg Res       Date:  2017-01-30       Impact factor: 2.192

4.  Associations of components of PTEN/AKT/mTOR pathway with cancer stem cell markers and prognostic value of these biomarkers in hepatocellular carcinoma.

Authors:  Rujuan Su; Haocheng Nan; Hui Guo; Zhiping Ruan; Lili Jiang; Yuanyuan Song; Kejun Nan
Journal:  Hepatol Res       Date:  2016-04-08       Impact factor: 4.288

5.  Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.

Authors:  Zi-Zhen Xu; Zu-Guang Xia; Ai-Hua Wang; Wen-Fang Wang; Zhi-Yin Liu; Li-Yun Chen; Jun-Min Li
Journal:  Ann Hematol       Date:  2013-05-02       Impact factor: 3.673

6.  Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.

Authors:  Meng-Hui Zhang; Hu Niu; Zheng Li; Ren-Tao Huo; Jun-Mei Wang; Jun Liu
Journal:  Cancer Biomark       Date:  2018       Impact factor: 4.388

7.  Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome.

Authors:  Eleftheria Lakiotaki; Georgia Levidou; Maria K Angelopoulou; Christos Adamopoulos; Gerassimos Pangalis; George Rassidakis; Theodoros Vassilakopoulos; Gabriella Gainaru; Pagona Flevari; Sotirios Sachanas; Angelica A Saetta; Athanasia Sepsa; Maria Moschogiannis; Christina Kalpadakis; Nikolaos Tsesmetzis; Vassilios Milionis; Ilenia Chatziandreou; Irene Thymara; Panayiotis Panayiotidis; Maria Dimopoulou; Eleni Plata; Konstantinos Konstantopoulos; Efstratios Patsouris; Christina Piperi; Penelope Korkolopoulou
Journal:  Sci Rep       Date:  2016-02-19       Impact factor: 4.379

8.  Prognostic implications of phosphatidylinositol 3-kinase/AKT signaling pathway activation in gastric carcinomas.

Authors:  Paula Blandina Ola Chiappini; Ivan Ucella Dantas de Medeiros; Luiz Guilherme Cenaglia Lima; Jose Humberto Fregnani; Suely Nonogaki; Wilson Luiz da Costa; Felipe Jose Fernandez Coimbra; Milton Jose de Barros E Silva; Celso Abdon Lopes de Mello; Clovis Antonio Lopes Pinto; Maria Dirlei Begnami
Journal:  Arch Med Sci       Date:  2016-06-07       Impact factor: 3.318

9.  The Expression and Prognostic Impact of the PI3K/AKT/mTOR Signaling Pathway in Advanced Esophageal Squamous Cell Carcinoma.

Authors:  Ning Wu; Zunguo Du; Yongjun Zhu; Yang Song; Liewen Pang; Zhiming Chen
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

10.  High density lipoprotein protects mesenchymal stem cells from oxidative stress-induced apoptosis via activation of the PI3K/Akt pathway and suppression of reactive oxygen species.

Authors:  Jianfeng Xu; Juying Qian; Xinxing Xie; Li Lin; Yunzeng Zou; Mingqiang Fu; Zheyong Huang; Guoping Zhang; Yangang Su; Junbo Ge
Journal:  Int J Mol Sci       Date:  2012-12-13       Impact factor: 5.923

View more
  2 in total

1.  ZNF191 alters DNA methylation and activates the PI3K-AKT pathway in hepatoma cells via transcriptional regulation of DNMT1.

Authors:  Yufeng Liu; Hanghang Cheng; Chenchen Cheng; Fengyun Zheng; Zhonghua Zhao; Qi Chen; Wenjiao Zeng; Pingzhao Zhang; Cheng Huang; Wei Jiang; Xiuping Liu; Guoyuan Liu
Journal:  Cancer Med       Date:  2022-01-28       Impact factor: 4.452

Review 2.  Emerging Roles for AKT Isoform Preference in Cancer Progression Pathways.

Authors:  Seamus E Degan; Irwin H Gelman
Journal:  Mol Cancer Res       Date:  2021-04-30       Impact factor: 5.852

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.